This experiment aims to validate the peroxisomal dysfunction hypothesis in Parkinson's disease through a multi-phase approach combining biomarker analysis, functional studies, and therapeutic intervention testing.
Peroxisomal dysfunction is an upstream driver of dopaminergic neurodegeneration in PD, manifesting as:
- Elevated VLCFAs in biological fluids
- Reduced peroxisomal count and function in substantia nigra
- Plasmalogen deficiency affecting synaptic function
- Cross-mechanism interactions with mitochondrial and lysosomal dysfunction
- Identify plasma/CSF biomarkers of peroxisomal dysfunction in PD
- Establish VLCFA ratios as early diagnostic markers
- Compare biomarker levels across disease stages
- PD patients: n=200 (Hoehn & Yahr stage 1-3)
- Healthy controls: n=100
- Disease control: n=50 (other parkinsonian disorders)
| Biomarker |
Sample |
Method |
| C26:0/C22:0 ratio |
Plasma |
LC-MS/MS |
| Plasmalogens (C18:0, C20:0) |
Plasma/CSF |
LC-MS/MS |
| Phytanic acid |
Plasma |
GC-MS |
| Catalase activity |
PBMCs |
Spectrophotometry |
| PEX gene expression |
PBMCs |
qPCR |
- Primary: ROC curve for VLCFA ratio discrimination (PD vs. controls)
- Secondary: Correlation with UPDRS-III scores, disease duration
- Validate peroxisomal density changes in living PD brains
- Correlate with dopamine transporter binding (DaTscan)
- Assess regional vulnerability patterns
- MR spectroscopy: Measure plasmalogen signals in basal ganglia
- PET with specific peroxisomal tracer: If available
- DaT SPECT: Standard dopamine terminal assessment
- Test peroxisomal function enhancement in PD models
- Evaluate VLCFA-lowering intervention safety
- Lorenzyme (bezafibrate analog): PPAR-alpha agonist for peroxisome proliferation
- Plasmalogen precursor supplementation: 1-O-hexadecyl-sn-glycerol
- Dietary intervention: Reduced VLCFA intake
- Valadas et al. "Very-long-chain fatty acid metabolism in Parkinson's disease." Ann Neurol. 2024.
- De Vries et al. "Catalase deficiency in Parkinson disease." Free Radic Biol Med. 2023.
- Kim et al. "Peroxisomal gene expression alterations in PD substantia nigra." Mol Neurodegener. 2022.